Log in to search using one of your social media accounts:

 

First-line ribociclib plus letrozole in postmenopausal women with HR+  , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

ConclusionRIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+  , HER2− ABC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

This article summarizes FDA decision-making and data supporting the approval of ribociclib. PMID: 29437768 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsFulvestrant 500  mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
We present an analysis of patient reports of these symptoms over the course of the trial, with fatigue as the central concept. We explicitly consider missing data, the relationships between symptoms, and the relationships with survival.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
CONCLUSIONS: SC trastuzumab is preferred by patients and the nursing staff versus the IV administration. The use of SC trastuzumab reduced the cost derived from trastuzumab administration. PMID: 28534353 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Purpose: Radiation therapy is an important treatment modality in the curative management of early stage breast cancer. With increasing cancer survivorship, late effects of cancer treatment have become increasingly relevant. Breast fibrosis is a common late effect following therapeutic irradiation which can potentially result in pain, poor cosmesis, and functional impairment. Randomized trials have suggested that radiation fibrosis may be reversible or preventable using a medication regimen of Pentoxifylline and Vitamin E. These clinical trials have shown excellent patient compliance and tolerability of this regimen, but it...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
CONCLUSIONS: The combination of oral continuous dosing of V (200 mg PO BID) with metronomic C (50, 75, 100 and 125 mg daily) is well tolerated and shows antitumor activity in patients with BRCA mutation associated MBC. The RPTD is C 125 mg daily plus V 200 mg BID, although further escalation of the C dose may be feasible since DLT was not seen at this dose level.canres;77/4_Supplement/P3-13-09/table1T1Dose LevelsDose Level# Patients/Evaluable# DLTType of DLTDL 1 :V 50mg , C 50mg3/30DL 2 :V 100 mg, C 50mg4/30DL 3 :V 200 mg, C 50mg6/61HeadacheDL 4 :V 300 mg, C 50mg6/52Nausea (N=2)DL 3A :V 200 mg; C 75mg3/30DL 3B :V 200 mg, C...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
This study evaluates efficacy and safety of radium-223 versus placebo (pbo), each + endocrine treatment (ET), in patients with HER2- estrogen receptor+ (ER+)bone-dominant MBC (NCT02258464). Patients receive (1:1) radium-223 50 kBq/kg IV or pbo q 4 wk (6 cycles) + ET + denosumab or bisphosphonates + best supportive care. Stratification is by geographic region (EU/N America vs Asia), number of prior ET lines (1 vs ≥ 2) for MBC, and number of prior skeletal-related events (SREs) (1 vs 2).Eligibility criteria: Eligible patients are pre- or postmenopausal with HER2- ER+ bone-dominant MBC and ≥ 2 bone mets or with soft tis...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Ongoing Clinical Trials Source Type: research
Background: Treatment options for bone-dominant metastatic breast cancer (MBC) are limited. Radium-223, a first-in-class α emitter with a targeted antitumor effect on bone metastases (mets), was well tolerated and reduced bone biomarker levels in a phase 2 study in patients with bone-dominant MBC (Coleman et al. Breast Cancer Res Treat. 2014). In patients with HER2- estrogen receptor+ (ER+) bone-dominant MBC, everolimus + exemestane (EVE+EXE) improved progression-free survival (PFS) versus EXE alone. Radium-223 combined with EVE+EXE may improve outcomes in patients with HER2- ER+ bone-dominant MBC; this trial will ev...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Ongoing Clinical Trials Source Type: research
Breast cancer progression is associated with systemic effects such as functional limitation, sarcopenia and cachexia. These effects are manifested as muscle weakness, body pain or depletion of skeletal muscle mass. Over a quarter of 2.8 million breast cancer patients in the United States experience a precachexia to cachexia syndrome. It has been reported that cancer-induced cytokines activate NF-κB, which promotes cancer progression, metastasis, and chemoresistance. These cytokines could potentially induce NF-kB in skeletal muscle, impair skeletal muscle function, and cause functional limitations. Therefore, NF-&kapp...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusion: Patients treated in Comprehensive Cancer Centres in the Czech Republic prefer subcutaneous application form of trastuzumab. The main reasons for their preference are time savings and better application comfort.Citation Format: Lindman H, Nilsson A, Gullbo J. Clinical characteristics of CNS metastases of different breast cancer subtypes – Results from a cohort study [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-12-09.
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Pain | Study | Women